Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13896 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Qiudi Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Roche Innovation Center, Shanghai, China. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Healthy Volunteers, Hepatitis B, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Ruzotolimod (Toll‐like receptor 7 (TLR7) agonist, RG7854) is an oral, small molecule immuno‐modulator activating the TLR 7 and is being evaluated in patients with CHB. As with other TLR7 agonists, the study drug‐related adverse events of flu‐like symptoms have been reported in some participants during phase I studies with ruzotolimod. An exploratory analysis of the relationship between pharmacokinetic (PK)/pharmacodynamic (PD) and flu‐like symptoms was performed in participants from two phase I studies including both healthy volunteers and NUC‐suppressed CHB patients who received either single or multiple ascending doses of orally administered ruzotolimod. Linear and logistic regression were used to explore potential relationships between dose, flu‐like symptoms, PK, and PD. Generalized linear regression was performed to predict the probability of flu‐like symptoms of all intensities at different RO7011785 (the active metabolite of the double prodrug ruzotolimod) PK exposure. This analysis showed that single or multiple doses of ruzotolimod at ⩾100 mg, the immune PD (IFN‐α, neopterin, IP‐10, and the transcriptional expression of ISG15, OAS‐1, MX1, and TLR7) responses increase with the RO7011785 PK exposure, which increases linearly with the doses from 3 mg to 170 mg of ruzotolimod. The analysis also showed that the probability of flu‐like symptoms occurrence increases with PD responses (IFN‐α and IP‐10). Dose reduction of ruzotolimod can be an effective way to reduce the magnitude of PD response, thus reducing the probability of study drug‐related flu‐like symptoms occurrence at all intensity in the participants who are highly sensitive to PD activation and intolerant to flu‐like symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Roche Innovation Center, Shanghai, China.
- Roche Innovation Center, Basel, Switzerland.
- Roche Innovation Center, Welwyn, UK.
- Roche Innovation Center, New York, New York, USA.
ORCID-Profile: Qiudi Jiang, Sylvie Retout, Katerina Glavini, Miriam Triyatni, Yonghong Zhu, Yuyan Jin
Zitieren
APA
Jiang, Q., Zhang, Y., Duan, D., Retout, S., Upmanyu, R., Glavini, K., Triyatni, M., Zhu, Y., Grippo, J. F., & Jin, Y. (2024). Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod. Clinical and Translational Science. https://doi.org/10.1111/cts.13896
Vancouver
Jiang Q, Zhang Y, Duan D, Retout S, Upmanyu R, Glavini K, et al. Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod. Clinical and Translational Science. 2024. doi:10.1111/cts.13896
BibTeX
@article{Jiang2024,
author = {Jiang, Qiudi and Zhang, Yuchen and Duan, Dan and Retout, Sylvie and Upmanyu, Ruchi and Glavini, Katerina and Triyatni, Miriam and Zhu, Yonghong and Grippo, Joseph F and Jin, Yuyan},
title = {Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13896}
}
EUVIMED